Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 151-161

  Buckley, Mitchell S ^a   Staib, Robin L ^a   Wicks, Laura M ^a   Feldman, Jeremy P ^b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b Arizona Pulmonary Specialists Ltd   (United States)

Author keywords

Pulmonary hypertension; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DIGOXIN; DIURETIC AGENT; DRUG METABOLITE; ILOPROST; NIFEDIPINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; VARDENAFIL;

6 MINUTE WALK DISTANCE; ANTERIOR NONISCHEMIC OPTIC NEUROPATHY; BACKACHE; BORG DYSPNEA SCORE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EISENMENGER COMPLEX; EXERCISE; FLUSHING; FUNCTIONAL ASSESSMENT; HEARING; HEART INDEX; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE MASS; HEMATOPHAGIC HISTIOCYTOSIS SYNDROME; HISTIOCYTOSIS; HUMAN; HYPOTENSION; HYPOXIA; IC 50; INSOMNIA; LIMB PAIN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MONOTHERAPY; MYALGIA; NAUSEA; OPTIC NERVE DISEASE; PARESTHESIA; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SUDDEN DEATH; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 78650691642     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S6215     Document Type: Review

References (48)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med. 1991;115:343-349.
2. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51:527-538.
3. Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther. 2007;29:2134-2153.
4. Badesch DB, Abman SH, Simonnequ G, Rubin LJ, McLaughlin VV. Medical therapy of pulmonary arterial hypertension. Chest. 2007;131:1917-1928.
5. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S-12S.
6. Simonneau G, Robbins IM, Geghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54: S43-S54.
7. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):13S-24S.
8. Traiger GL. Pulmonary arterial hypertension. Crit Care Nurs Q. 2007;30:20-43.
9. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431.
10. Hackman AM, Lackner TE. Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years. Pharmacotherapy. 2006;26:68-94.
11. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
12. Sirbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
13. Croom KF, Curran MP. Sildenafil: A review of its use in pulmonary arterial hypertension. Drugs. 2008;68:383-397.
14. Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: Rationale and place in therapy. Am J Cardiovasc Drugs. 2008;8:171-185.
15. Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med. 2005;99:1501-1510.
16. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005;96:1334-1336.
17. Kataoka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J. 2005;69:461-465.
18. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007;120:301-305.
19. Oudiz RJ, Roveran G, Hansen JE, Sun XG, Wasserman K. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Int J Cardiol. 2007;9:917-921.
20. Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008;21:824-832.
21. Chapman TH, Wilde M, Madden SB. Sildenafil therapy in secondary pulmonary hypertension: Is there a benefit in prolonged use? Vascul Pharmacol. 2009;51:90-95.
22. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
23. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108:2066-2069.
24. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long- term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158-164.
25. Chcokalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol. 2005;99:91-95.
26. Wilkins H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-1222.
27. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
28. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to longterm intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med. 2008;149:521-530.
29. Bharani A, Mathew V, Sahu A, Lunia B. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. 2003;55:55-59.
30. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebocontrolled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
31. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292-1297.
32. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1-e5.
33. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136:515-522.
34. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol. 2004;44:1488-496.
35. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-2903.
36. Bharani A, Patel A, Saraf J, Jain A, Mehrotra S, Lunia B. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J. 2007;59:323-328.
37. Kass DA, Takimoto E, Nagayuma T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res. 2007;75:303-314.
38. Wilkins MR, Wharton J, Grimminger F, Ghofrani H. Phosphodiesterase inhibitors in the treatment of pulmonary hypertension. Eur Respir J. 2008;32:198-209.
39. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864-1871.
40. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453-459.
41. Gresser U, Gleiter CH. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil: Review of the literature. Eur J Med Res. 2002;7:435-446.
42. Katz SD. Tadalafil: The evidence for its clinical potential in the treatment of pulmonary arterial hypertension. Core Evidence. 2008;2:225-231.
43. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep. 2003;4:457-465.
44. Revatio® (sildenafil) package insert. New York, NY: Pfizer Labs; 2009 Nov. Accessed Mar 2010.
45. Cialis® (tadalafil) package insert. Indianapolis, IN: Eli Lilly and Company; May 2009. Accessed Mar 2010.
46. Levitra® (vardenafil) package insert. Wayne, NJ: Bayer Healthcare Pharmaceuticals; Dec 2008. Accessed Mar 2010.
47. Giuliano F, Varanese L. Tadalafil: A novel treatment for erectile dysfunction. Eur Heart J Suppl. 2002;4:H24-H31.
48. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:78-84.